Pulsenmore Ltd.
No SEC Form 4 filings for $PLSM in the last 30 days.
See all $PLSM insider activity →Pulsenmore Ltd. (PLSM) appointed David Woods as Chief Commercial Officer to support U.S. expansion. Woods has 25 years of medtech experience. The company aims to grow in the American healthcare market, targeting underserved areas. Shares rose 1.11% to $1.8402 on Nasdaq.
Pulsenmore (NASDAQ: PLSM, TASE: PLSM) has expanded its fertility platform into the UK after completing MHRA registration for its home ultrasound system, Pulsenmore FC. The system allows women undergoing IVF to perform vaginal ultrasound scans at home, reducing clinic visits. The UK market saw over 100,000 fertility treatment cycles in 2024, according to the HFEA.
Pulsenmore Ltd. (Nasdaq: PLSM) (TASE: PLSM) has completed CE European registration for its home ultrasound system, Pulsenmore FC, expanding into fertility care. The system allows patients to perform scans at home, reducing clinic visits. Over 1.15 million assisted reproduction treatment cycles were reported in Europe in 2023, with many requiring repeated ultrasounds. The company aims to market the system across Europe, following approval in Israel and a commercial agreement with Clalit Health Se
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PLSM (Pulsenmore Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PLSM coverage spans regulation, technology and financial news.
Leadership and U.S. commercialization expansion could support near-term revenue expectations, but the article provides no financial targets or measurable guidance.
Regulatory clearance opens a new market, potentially boosting revenue and expanding the addressable base.
The registration unlocks a new market segment, potentially expanding revenue and market share in women's health.
First‑time earnings disclosure for a micro‑cap with modest revenue growth and a capital raise; potential upside if commercialization in the U.S. accelerates.
The rollout adds a new clinical site but does not include financial terms or large-scale contracts.
AlphAI scores every news story that mentions PLSM with an AI model for sentiment and relevance, and aggregates insider trades from Pulsenmore Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulsenmore Ltd. (PLSM) appointed David Woods as Chief Commercial Officer to support U.S. expansion. Woods has 25 years of medtech experience. The company aims to grow in the American healthcare market, targeting underserved areas. Shares rose 1.11% to $1.8402 on Nasdaq.
2 min readPulsenmore (NASDAQ: PLSM, TASE: PLSM) has expanded its fertility platform into the UK after completing MHRA registration for its home ultrasound system, Pulsenmore FC. The system allows women undergoing IVF to perform vaginal ultrasound scans at home, reducing clinic visits. The UK market saw over 100,000 fertility treatment cycles in 2024, according to the HFEA.
2 min readPulsenmore Ltd. (Nasdaq: PLSM) (TASE: PLSM) has completed CE European registration for its home ultrasound system, Pulsenmore FC, expanding into fertility care. The system allows patients to perform scans at home, reducing clinic visits. Over 1.15 million assisted reproduction treatment cycles were reported in Europe in 2023, with many requiring repeated ultrasounds. The company aims to market the system across Europe, following approval in Israel and a commercial agreement with Clalit Health Se
2 min readPulsenmore Ltd. (PLSM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update Omer, Israel –August 31, 2026 – Pulsenmore Ltd. (Nasdaq/TASE: PLSM ), a leadin
2 min readPulsenmore (NASDAQ: PLSM, TASE: PLSM) announced its home ultrasound technology will be integrated at Lis Maternity and Women's Hospital at Ichilov in Israel, expanding access to at-home pregnancy monitoring. This move broadens the company's presence in central Israel and supports its hybrid monitoring model, combining hospital and at-home care. Pulsenmore's technology aims to improve maternal health by enabling remote ultrasound scans under medical guidance.
1 min readPulsenmore Ltd. (NASDAQ:PLSM) shares jumped about 160% after the company said it was selected for Israel’s Healthcare AI Regulatory Sandbox Program by the Israel Innovation Authority and Ministry of Health. Pulsenmore will receive funding for a $1 million project to develop and clinically validate AI for its home ultrasound platform, with Beilinson Hospital/Clalit Health Services.
3 min read
